63 Biggest Movers From Yesterday
Gainers
Support.com, Inc. (NASDAQ: SPRT) shares surged 41.1% to settle at $19.70 on Thursday on abnormally high volume.
Cabaletta Bio’s Cell Therapy Shows Encouraging Safety Profile In Autoimmune Skin Disorder
Cabaletta Bio Inc (NASDAQ:CABA) has announced 28-day data from the second dose cohort from the DesCAARTes Phase 1 trial of DSG3-CAART…
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Cabaletta Bio Reports Clinical Data From Second Dose Cohort In DesCAARTes Trial In Patients With mPV
– No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort–
– DSG3-CAART persistence observed in
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Cabaletta Bio Q2 EPS $(0.45) Down From $(0.35) YoY
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.45) per share. This is a 28.57 percent decrease over losses of $(0.35) per share from the same period last year.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's morning session saw 58 companies set new 52-week lows.
Mizuho Initiates Coverage On Cabaletta Bio with Buy Rating, Announces Price Target of $22
Mizuho analyst Vamil Divan initiates coverage on Cabaletta Bio (NASDAQ:CABA) with a Buy rating and announces Price Target of $22.